Limited proven treatment options exist for patients with metastatic breast cancer (MBC) resistant to anthracycline and taxane treatment. Ixabepilone, a novel semisynthetic analog of epothilone B, has demonstrated single-agent activity in MBC resistant to anthracyclines and taxanes. In combination with capecitabine in a phase III trial (CA163-046) in this setting, ixabepilone prolonged progression-free survival and increased objective response rate relative to capecitabine (Thomas et al. J Clin Oncol 25:5210-5217, 2007). Here, we report the results of overall survival (OS), a secondary efficacy endpoint from the CA163-046 trial. Seven hundred fifty-two patients with MBC resistant to anthracyclines and taxanes were randomized to ixabepilone (40 mg/m2 intravenously on day 1 of a 21-day cycle) plus capecitabine (2,000 mg/m 2 orally on days 1 through 14 of a 21-day cycle) or capecitabine alone (2,500 mg/m2 on the same schedule). Patients receiving ixabepilone plus capecitabine treatment had a median survival of 12.9 months compared to 11.1 months for patients receiving capecitabine alone (HR = 0.9; 95%CI: 077-1.05; P = 0.19). This observed increase in median OS favored the combination; however, the difference was not statistically significant. Predefined subset analyses showed a clinically meaningful increase in OS in KPS 70-80 patients receiving ixabepilone plus capecitabine (HR = 0.75; 95% CI: 0.58-0.98). Ixabepilone plus capecitabine did not show a significant improvement in survival compared to capecitabine alone in patients with MBC resistant to anthracyclines and taxanes. The observed differences in survival favored the combination arm. A clinical benefit was also seen in patients in the KPS 70-80 subgroup (ClinicalTrials.gov number, NCT000080301).
Bibliographical noteFunding Information:
Acknowledgments CA163-046 was funded by Bristol-Myers Squibb. The authors wish to thank the patients and all the investigators who participated in the study. Professional medical writing and editorial assistance provided by Ananya Bhattacharya, employee of Bristol-Myers Squibb. The authors vouch for the completeness and accuracy of results presented.
Conflict of interest statement GH has served as a consultant for Bristol-Myers Squibb and Novartis and has a commercial research grant from Novartis; LF has served as a consultant for Bristol-Myers Squibb; VC has received honoraria from Eli Lilly and Novartis and has served as a consultant for Astra Zeneca; JJ has served as a consultant for Bristol-Myers Squibb and Glaxo SmithKleine; XP has received honoraria from Roche, Glaxo SmithKleine, and Novartis, has served as a consultant for Roche and has received commercial research support from Roche; LV has received honoraria from Bristol-Myers Squibb, commercial research grant from Bristol-Myers Squibb, Curagen, Imclone, and Glaxo SmithKleine, and has served as a consultant for Bristol-Myers Squibb, Bayer, and Onyx; HG, RKL, HCC GL, FM BX, and HR have no financial relationships to disclose; RP and PM are employees of Bristol-Myers Squibb.
All Science Journal Classification (ASJC) codes
- Cancer Research